Compare TIL & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIL | HNNA |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 83.2M |
| IPO Year | 2021 | N/A |
| Metric | TIL | HNNA |
|---|---|---|
| Price | $7.09 | $9.99 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $125.00 | N/A |
| AVG Volume (30 Days) | ★ 262.8K | 19.8K |
| Earning Date | 03-03-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 5.37% |
| EPS Growth | N/A | ★ 38.04 |
| EPS | N/A | ★ 1.27 |
| Revenue | N/A | ★ $35,538,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.06 |
| Revenue Growth | N/A | ★ 19.88 |
| 52 Week Low | $5.67 | $8.43 |
| 52 Week High | $42.79 | $13.19 |
| Indicator | TIL | HNNA |
|---|---|---|
| Relative Strength Index (RSI) | 32.88 | 52.61 |
| Support Level | $6.79 | $10.01 |
| Resistance Level | $7.32 | $10.87 |
| Average True Range (ATR) | 0.26 | 0.30 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 48.87 | 48.41 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.